Cin Nasara Kan Babban Lymphoma na B-Cell Tare da Bioocus Dual CAR-T Therapy

Bayanin Majiyyaci

Rodney, mutum mai juriya daga ƙasashen waje, an gano yana da cutar Diffuse Large B-Cell Lymphoma (DLBCL), wani nau'in cutar lymphoma wanda ba Hodgkin ba ne. Yana da shekaru 68, ya nemi hanyoyin magani na zamani bayan da magungunan gargajiya suka gaza. An tura shi zuwa cibiyar haɗin gwiwarmu a Asibitin Ciwon daji na Tianjin, Rodney ya yi rajista a cikin tsarin maganin CAR-T na Bioocus mai lamba P1549. Wannan maganin yana mai da hankali kan ƙwayoyin cutar kansa guda biyu, yana ba da hari mai kusurwa biyu don haɓaka inganci da rage haɗarin sake dawowa.

Tafiyar Maganin

Maganin Rodney ya fara ne a watan Satumba na 2025 tare da shigar da ƙwayoyin CAR-T masu aiki waɗanda aka ƙera don bayyana masu karɓar antigen na chimeric don CD19 da CD20. Tsarin ya haɗa da tattara samfurin jininsa na gefe (PB), sarrafa shi don ƙirƙirar ƙwayoyin CAR-T na musamman, da kuma zuba wani magani da ya dace da buƙatunsa. Bayan an yi masa allurar, an sa ido sosai kan ci gabansa ta hanyar gwaje-gwajen jini na jere a ranakun da aka bi diddigin su: Rana ta 4 (D4), Rana ta 7 (D7), da Rana ta 10 (D10).

• D4 (12 ga Satumba, 2025):Ganowar farko ta nuna ƙaramin kasancewar ƙwayoyin CAR-T, tare da ƙwayoyin CD19+ CAR-T a 0.50% na ƙwayoyin CD3+ T (ƙimar cikakke: 6.04 × 10^6/L) da ƙwayoyin CD20+ CAR-T a 0.41% (ƙimar cikakke: 4.96 × 10^6/L). Wannan matakin farko ya nuna nasarar yin zane.
• D7 (15 ga Satumba, 2025):Faɗaɗawa ta yi sauri, inda ƙwayoyin CD19+ CAR-T suka tashi zuwa 1.68% (ƙimar cikakke: 1.40 × 10^7/L) da ƙwayoyin CD20+ CAR-T zuwa 1.63% (ƙimar cikakke: 1.36 × 10^7/L), suna nuna ƙaruwa mai ƙarfi.
• D10 (Satumba 18, 2025):An lura da faɗaɗar kololuwar gani mai ban mamaki, inda ƙwayoyin CD19+ CAR-T suka kai kashi 31.43% na ƙwayoyin CD3+ T (ƙimar cikakke: 3.13 × 10^8/L) da ƙwayoyin CD20+ CAR-T a kashi 32.74% (ƙimar cikakke: 3.26 × 10^8/L). Binciken ƙananan abubuwa ya nuna daidaiton rarrabawa a cikin ƙwayoyin CD4+ da CD8+ T, tare da jimlar adadin ƙwayoyin T a 2.9 × 10^9/L, gami da 34.35% ƙwayoyin CD3+ T.

A duk lokacin da aka yi la'akari da wannan, yanayin garkuwar jikin Rodney ya nuna canje-canje masu kyau, kamar ƙaruwar ƙwayoyin T masu guba (CD3+CD8+ a 69.56%), wanda hakan ya nuna ikon da maganin ke da shi na ƙarfafa garkuwar jikinsa don yaƙar cutar sankarar lymphocyte.

Sakamako Masu Kyau

Da D10, ƙaruwar ƙwayoyin CAR-T mai ƙarfi—fiye da sau 500 a cikin adadin da aka samu daga D4—ya nuna ƙarfin aikin maganin na hana ƙari. Wannan faɗaɗa cikin sauri alama ce ta nasarar maganin CAR-T, wanda galibi yana da alaƙa da sassauci mai zurfi da ɗorewa ga marasa lafiya na DLBCL. Rodney ya jure wa maganin sosai, ba tare da an bayar da rahoton manyan matsaloli ba a matakin sa ido. Shari'arsa ta nuna misalin hanyar Bioocus ta CAR-T guda biyu, wadda ta sami babban cikakken amsawa (CR) da kuma yawan amsawa gaba ɗaya (ORR) a cikin ƙungiyar marasa lafiya ta duniya.